November 5, 2019
The checkpoint inhibitor pembrolizumab (Keytruda) increases the survival time of patients with advanced head and neck cancers, according to a new global study led by Yale Cancer Center (YCC). The data was published in the journal The Lancet. The findings of the phase 3 study show that, compared to the standard […]
